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Abstract
Approved in 1989 for the management of treatment-resistant schizophrenia, Clozapine is a last-line atypical antipsychotic
drug used with increasing frequency. In addition to its well-known side effect of agranulocytosis, this drug also carries with
it rare but serious adverse cardiovascular risk of myocarditis. We present a patient on Clozapine who was admitted to the
cardiology service with chest pain, ST segment elevations and elevated troponin concerning for acute myocardial infarction.
Evaluation with imaging revealed decreased left ventricular function, however, no coronary artery disease was present on
catheterization; ﬁndings consistent with a diagnosis of myocarditis. Subsequent discontinuation of the patient’s Clozapine
and initiation of brief supportive medical therapy resulted in full recovery of systolic left ventricular function. Given the
potential cardiovascular mortality risk, it is important for physicians on cardiology services caring for psychiatric patients to
be aware of the presentation of symptoms, diagnostic ﬁndings and management of Clozapine induced myocarditis.

INTRODUCTION

CASE REPORT

Clozapine is a last-line atypical antipsychotic agent used to
treat patients with difﬁcult to treat schizophrenia. It is classically known for its potential serious side effects of agranulocytosis, however also carries a boxed warning for an uncommon,
but important association with adverse cardiovascular effects,
namely myocarditis [1, 2]. In recent reviews, the incidence of
myocarditis associated with Clozapine exposure is 3% [3, 4]. We
report a case of a 40-year-old female started on Clozapine with
subsequent development of myocarditis potentially relating to
this agent. We focus in this vignette on the clinical management
in a cardiac service as well as provide a brief literature review to
understand the possible pathophysiology of Clozapine induced
cardiotoxicity.

A 40-year-old transgender male to female with history of schizophrenia initially presenting for suicidal ideation was admitted to
the inpatient psychiatric unit. She was enrolled in the Clozapine
risk evaluation and modiﬁcation strategy program and started
on the drug 7 days after admission. The medication was uptitrated to 50 mg in the morning and 150 mg at night. On Day 9,
she reported chest pain. An EKG demonstrated new marked ST
segment elevations in leads I, avL, II, and V4-V6 (see Figs 1 and
2). Laboratory results revealed elevated troponin of 12 ng/ml
(normal range 0.000–0.034) and creatine kinase MB (CKMB) of
48 ng/ml (normal range 0.00–2.30). Given the EKG ﬁndings suggestive of acute ST segment elevation myocardial infarction
(STEMI), she was transferred to our cardiac service.
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Figure 1: EKG prior to Clozapine initiation.

Figure 2: EKG during chest pain event after Clozapine therapy.

On initial evaluation, the patient described substernal chest
pressure. Her past medical history revealed no cardiovascular
disease risk factors. She denied having fevers, chills or upper
respiratory symptoms. Her medication list included Clozapine,
and prior single doses of Hydroxyzine, Haloperidol and
Lorazepam. She took no medications at home. Her vital signs
were stable, cardiac examination was normal. In addition to
elevated troponin and CKMB, labs showed elevated brain natriuretic peptide (BNP) of 3070 pg/ml, erythrocyte sedimentation
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rate (ESR) of 30 mm/h and C-reactive protein (CRP) of 36 mg/dl.
An upper respiratory PCR panel was negative for inﬂuenza A/B
and other viruses. A urine analysis revealed no signs of infection. A chest x-ray was unremarkable.
The patient was taken immediately to the catheterization
lab and no occlusive coronary artery disease was seen. A transthoracic echocardiogram revealed ejection fraction of 30–35%
with moderate global hypokinesis. Given high suspicion for
drug induced myocarditis, Clozapine was stopped. The patient

Clozapine-induced myocarditis
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Figure 3: Timeline of events.

was monitored on telemetry and started on cardiac medical
management with low doses of Metoprolol (12.5 mg twice a
day) and Lisinopril (2.5 mg daily).
She remained chest pain free through the remainder of her
course without development of shortness of breath, orthopnea
or lower extremity swelling. On hospital Day 20 (4 days after
discontinuation of Clozapine) a repeat transthoracic echocardiogram showed fully recovered left ventricular function with
an ejection fraction of 65% and no wall motion abnormalities.
Timeline of Events is shown in Fig. 3. Cardiac medications
were discontinued and ventricular function remained recovered. The patient was transferred back to the psychiatry
inpatient team in stable condition for further management of
her schizophrenia.

DISCUSSION
Development of myocarditis as a result of Clozapine therapy
generally occurs within the ﬁrst 2–8 weeks of therapy [5]. At
time of diagnosis, the mean age of patients has been reported
as 33.5 years with mean dose of Clozapine 360 mg [6]. Rule out
of other etiologies of myocarditis/inﬂammatory cardiomyopathy with testing for viral respiratory infection, autoimmune
diseases and giant cell myocarditis is imperative [7–9].
Laboratory testing to look for myocardial damage with elevated
cardiac enzymes as well as evaluation of electrocardiogram
and chest x-ray are standard measures. In our case, the diffuse
ST segment elevations on electrocardiogram are seen with pericarditis however taking the entire clinical picture into context,
myocarditis remained the leading diagnosis. Supportive evidence additionally includes elevated BNP and absence of hypertension or history of valvular disease. Echocardiogram to
assess ventricular function and provide conﬁrmation of developing ventricular failure is also helpful [5]. In the presence of
reduced systolic function, a cardiac catheterization to conﬁrm
lack of obstructive or ischemic coronary disease further conﬁrms a diagnosis of myocarditis. The role of re-challenging a
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patient with Clozapine after myocarditis is controversial. While
there have been mixed results, there are not enough cases with
rechallenge reported to draw deﬁnitive conclusions. The decision depends upon patient discussion to weigh quality of life
without Clozapine therapy versus risk of myocarditis on rechallenge. We did not rechallenge our patient. A major limitation in
our diagnosis was the inability to obtain cardiac magnetic resonance imaging. In the absence of endomyocardial biopsy, this
modality is important. Lastly, we could not conﬁrm that the
patient was not abusing any other substances no longer available once admitted, contributing to functional recovery.
Management of clozapine myocarditis is supportive and
empiric [6]. Once the diagnosis is established, if drug induced
myocarditis is suspected, the inciting agent should be discontinued immediately. Administration of diuretics, beta blockers
and angiotensin converting enzyme inhibitors have been
shown to support myocardial function during the acute myocardial insult [5]. Trending levels of inﬂammatory markers such
as ESR and CRP have been suggested as ways to document
recovery [10].
Discontinuation of Clozapine leads to cardiac functional
recovery with a direct correlation in degree of compromised
systolic function to degree of recovery, however mortality is
still 12.5–24% [4, 6, 11]. The timeline of onset of cardiac functional recovery from the time of discontinuation of drug is variable. Discontinuation of Clozapine should be done with close
liason with Psychiatry colleagues as relapse of Schizophrenia
may ensue leading to signiﬁcant patient harm.
The mechanism of Clozapine induced myocarditis has not
been well established. Links with geographical region based on
ozone concentrations, genetic predisposition, Ig E mediated
hypersensitivity and elemental deﬁciencies have been proposed. In a review conducted of 47 cases of Clozapine induced
myocarditis, the development of eosinophilia suggesting IgE
mediated hypersensitivity reaction has been documented in
~66% of cases [10]. The highest rates of Clozapine induced cardiomyopathy have been reported in New Zealand and Australia
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possibly due to possibly increased blockade of M2 receptors
and cholinergic receptor dysfunction in these areas of higher
ozone concentrations [12]. Genetic predisposition is thought to
be mediated by mutations in pharmacokinetic enzymes
CYP450-1A2 and CY450-1A3 [6].
To further consider is inherent alpha-adrenergic blocking
effects of antipsychotics [4]. This is supported by the fact that
patients prescribed Clozapine are those exposed to many antipsychotics before initiation of this last line agent suggesting
some degree of cumulative effect.
The role of sophisticated monitoring systems dedicated to
detecting cardiovascular complications associated with clozapine has been established. Protocols focus mainly on keeping a
high index of suspicion for early recognition of symptoms [13].
Ongoing discussions remain to include cardiac markers in
weekly blood work along with markers of inﬂammation in
these protocols.
In summary, our case highlights a rare yet potentially fatal
cardiovascular complication potentially relating to Clozapine
use. Recent cohort studies have shown that myocarditis and
sudden cardiac death are uncommon in patients maintained
on clozapine however given the fatal clinical signiﬁcance, preventive measures need to be further studied [14]. Given lethal
risk and boxed warning for cardiovascular toxicity, chest discomfort in a patient commencing Clozapine should be investigated for a symptom of myocarditis.
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